A Phase 2/3 interventional study of CP-945,598 and sibutramine in Obesity, sponsored by Pfizer. Completed at 15 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-08-12.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
To evaluate the effect of 6-month administration of CP-945,598 on:
1,766 studies on the registry are indexed under Weight Loss; 277 are open to participants now.
This study's enrollment of 282 is above the median of 73 across 1,496 interventional studies indexed under Weight Loss.
Browse Weight Loss studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Determine the effect of various doses of CP 945,598 on body weight in obese subjects after 24 weeks of dosing
Evaluate the safety and tolerability of CP 945,598 in a 26 week outpatient setting;; -Explore the effect of CP 945,598 on: waist circumference, PD measurements of selected biochemical variables related to energy deficit and weight loss includ
This study is completed, as verified in Apr 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer